Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Feb;38(2):378–380. doi: 10.1128/aac.38.2.378

In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles.

M C Cruz 1, M S Bartlett 1, T D Edlind 1
PMCID: PMC284462  PMID: 8192471

Abstract

Ten benzimidazole derivatives and amphotericin B were tested in vitro against three isolates of Cryptococcus neoformans. Drug concentrations inhibiting 50% of growth (IC50s) were determined. Four derivatives, including mebendazole and albendazole, had moderately high activities (IC50 = 0.1 to 0.3 microgram/ml). Fenbendazole, however, was 10-fold more active (IC50 = 0.01 to 0.02 microgram/ml) and also 2-fold more active than amphotericin B. Ten additional clinical isolates of C. neoformans were tested against fenbendazole, mebendazole, and albendazole; similar susceptibilities were observed. Drug concentrations lethal to 90% of the cells (LC90s) were determined for two isolates. The LC90s of albendazole and mebendazole were 0.92 to 2.1 micrograms/ml, and those of fenbendazole were 0.06 to 0.07 microgram/ml; the latter are eight to ninefold lower than the LC90s of amphotericin B that were obtained. Spontaneously arising mutants displaying partial resistance to fenbendazole arose at a low frequency (5 x 10(-9).

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett M. S., Edlind T. D., Durkin M. M., Shaw M. M., Queener S. F., Smith J. W. Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii. Antimicrob Agents Chemother. 1992 Apr;36(4):779–782. doi: 10.1128/aac.36.4.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Edlind T. D., Hang T. L., Chakraborty P. R. Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro. J Infect Dis. 1990 Dec;162(6):1408–1411. doi: 10.1093/infdis/162.6.1408. [DOI] [PubMed] [Google Scholar]
  3. Fling M. E., Kopf J., Tamarkin A., Gorman J. A., Smith H. A., Koltin Y. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet. 1991 Jun;227(2):318–329. doi: 10.1007/BF00259685. [DOI] [PubMed] [Google Scholar]
  4. Juliano C., Martinotti M. G., Cappuccinelli P. "In vitro" effect of microtubule inhibitors on Trichomonas vaginalis. Microbiologica. 1985 Jan;8(1):31–42. [PubMed] [Google Scholar]
  5. Jung H., Hurtado M., Sanchez M., Medina M. T., Sotelo J. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. Clin Neuropharmacol. 1990 Dec;13(6):559–564. doi: 10.1097/00002826-199012000-00008. [DOI] [PubMed] [Google Scholar]
  6. Jung M. K., Wilder I. B., Oakley B. R. Amino acid alterations in the benA (beta-tubulin) gene of Aspergillus nidulans that confer benomyl resistance. Cell Motil Cytoskeleton. 1992;22(3):170–174. doi: 10.1002/cm.970220304. [DOI] [PubMed] [Google Scholar]
  7. Kovacs J. A., Kovacs A. A., Polis M., Wright W. C., Gill V. J., Tuazon C. U., Gelmann E. P., Lane H. C., Longfield R., Overturf G. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Oct;103(4):533–538. doi: 10.7326/0003-4819-103-4-533. [DOI] [PubMed] [Google Scholar]
  8. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol. 1988 Nov;18(7):885–936. doi: 10.1016/0020-7519(88)90175-0. [DOI] [PubMed] [Google Scholar]
  9. Maxwell W. A., Brody G. Antifungal activity of selected benzimidazole compounds. Appl Microbiol. 1971 May;21(5):944–945. doi: 10.1128/am.21.5.944-945.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Panther L. A., Sande M. A. Cryptococcal meningitis in the acquired immunodeficiency syndrome. Semin Respir Infect. 1990 Jun;5(2):138–145. [PubMed] [Google Scholar]
  11. Paulsen I. T., Skurray R. A. Topology, structure and evolution of two families of proteins involved in antibiotic and antiseptic resistance in eukaryotes and prokaryotes--an analysis. Gene. 1993 Feb 14;124(1):1–11. doi: 10.1016/0378-1119(93)90755-r. [DOI] [PubMed] [Google Scholar]
  12. Powderly W. G. Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S54–S59. doi: 10.1093/clinids/14.supplement_1.s54. [DOI] [PubMed] [Google Scholar]
  13. Robinson H. J., Silber R. H., Graessle O. E. Thiabendazole: toxicological, pharmacological and antifungal properties. Tex Rep Biol Med. 1969 Nov;27(Suppl):537+–537+. [PubMed] [Google Scholar]
  14. Sugar A. M., Stern J. J., Dupont B. Overview: treatment of cryptococcal meningitis. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S338–S348. doi: 10.1093/clinids/12.supplement_3.s338. [DOI] [PubMed] [Google Scholar]
  15. Summerbell R. C. The benomyl test as a fundamental diagnostic method for medical mycology. J Clin Microbiol. 1993 Mar;31(3):572–577. doi: 10.1128/jcm.31.3.572-577.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Van den Bossche H., Rochette F., Hörig C. Mebendazole and related anthelmintics. Adv Pharmacol Chemother. 1982;19:67–128. doi: 10.1016/s1054-3589(08)60021-6. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES